- Advocacy in Action: NIH Funding, Physician Payment Changes, the EPA, and More...
- Heir on the Side of Caution: How a Von Hippel-Lindau Patient Is Managing Her Health–In the two decades since Stacy Lloyd was diagnosed with the Von Hippel-Lindau, much has changed in genetic research, treatment, and counseling methods.
- Positive Top-Line Results Announced from the Pivotal Phase 3 SONICS Study of Levoketoconazole for the Treatment of Endogenous Cushing’s Syndrome
- Celebrating the New and Improved Bicoastal Clinical Endocrinology Update!
- CEU Preview: Controversies Continue to Confound Testosterone Therapy
We are now accepting applications for the Future Leaders Advancing Research in Endocrinology (FLARE).
This program seeks graduate students, post-doctoral fellows, clinical fellows and junior faculty from underrepresented minority communities who have demonstrated achievement in endocrine research.
Do you have a colleague who has gone above and beyond in their seminal research, meritorious service, leadership and mentorship, innovation, internal contributions, public service, and lifetime achievement?
Submit nominations for our Laureate Awards by December 16, 2018.
Join our movement leading hormone science and medicine toward the goal of improved human health worldwide and save 50% on your membership.
Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma
MELK is overexpressed in human adrenocortical carcinoma cells and drives proliferation, tumorigenesis, and survival in a hypoxic environment. MELK is a therapeutic target for patients with ACC.
Noradrenergic Activity in the Human Brain: A Mechanism Supporting the Defense Against Hypoglycemia
Hypoglycemia increases noradrenergic activity in the raphe nuclei, whereas changes in hypothalamic noradrenergic activity correlate with the counterregulatory response to hypoglycemia in humans.
Lessons From the Testosterone Trials
The Testosterone Trials were conducted to determine if testosterone treatment would benefit older men with low testosterone. This report describes the Trials’ development and results and the lessons learned.
Everolimus Directly Suppresses Insulin Secretion Independently of Cell Growth Inhibition
Both a clinical case patient with metastatic insulinoma and in vitro experiments demonstrated that everolimus directly suppresses insulin secretion, independently of its tumor regression effect.